Xiao Ge
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Xiao Ge has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
Akihisa Nakagawa
Department of Molecular, Cellular and Developmental Biology, University of Colorado, Boulder, CO 80309, USA
1 shared publication- Chengjun Gan
Department of Respiratory and Critical Care Medicine, Second People’s Hospital of Wuwei, Wuwei, China
1 shared publication - Chunbo Zhao
Abdominal Radiotherapy Department, Harbin Medical University Cancer Hospital, Harbin Medical University, Harbin, China
1 shared publication - Ding Xue
Department of Molecular, Cellular, and Developmental Biology, University of Colorado, Boulder, CO 80309, USA
1 shared publication - Fang Ding
College of Automobile and Rail, Anhui Technical College of Mechanical and Electrical Engineering, Wuhu 241000, China
1 shared publication - Haipeng Gong
MOE Key Laboratory of Bioinformatics, School of Life Sciences Tsinghua University Beijing China
1 shared publication
Latest Publications
- Open Access
- 15 August 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (33) , e43836
Risk stratification for Pseudomonas LRTI in immunocompromised patients: A LASSO-logistic regression model with clinical implications
This retrospective cohort study examined 28-day mortality predictors among 177 immunocompromised adults with acute Pseudomonas aeruginosa lower respiratory tract infections (LRTIs) over a 6-year observational period. LASSO regression followed by logistic regression analysis was used to screen 19 clinical and laboratory variables. To evaluate the predictive performance of the model, ROC analysis was performed. Six independent mortality predictors emerged: neutrophil count, D-dimer-to-lymphocyte ratio (DLR), admission aspartate aminotransferase (AST), age, red cell distribution width (RDW), and platelet-to-lymphocyte ratio (PLR). The predictive model demonstrated robust discrimination (AUC = 0.792) with 91.9% sensitivity and 89.5% specificity at the optimal cutoff. The neutrophil-DLR-AST triad emerged as a novel prognostic combination reflecting systemic inflammation, coagulopathy, and hepatic stress. This study identifies 6 clinically accessible biomarkers for mortality risk stratification in immunocompromised hosts with P aeruginosa LRTI, with the neutrophil-DLR-AST triad representing a new prognostic model. The developed model offers clinicians a practical tool for early high-risk patient identification and personalized management. While highlighting the interaction between inflammatory regulation, coagulation abnormalities, and organ dysfunction in determining outcomes, these findings require prospective validation in multicenter cohorts. Future research should elucidate the pathophysiological mechanisms linking these biomarkers to disease progression and explore targeted interventions based on individualized risk profiles.
- 15 August 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (33) , e43836
Open AccessRisk stratification for Pseudomonas LRTI in immunocompromised patients: A LASSO-logistic regression model with clinical implications
This retrospective cohort study examined 28-day mortality predictors among 177 immunocompromised adults with acute Pseudomonas aeruginosa lower respiratory tract infections (LRTIs) over a 6-year observational period. LASSO regression followed by logistic regression analysis was used to screen 19 clinical and laboratory variables. To evaluate the predictive performance of the model, ROC analysis was performed. Six independent mortality predictors emerged: neutrophil count, D-dimer-to-lymphocyte ratio (DLR), admission aspartate aminotransferase (AST), age, red cell distribution width (RDW), and platelet-to-lymphocyte ratio (PLR). The predictive model demonstrated robust discrimination (AUC = 0.792) with 91.9% sensitivity and 89.5% specificity at the optimal cutoff. The neutrophil-DLR-AST triad emerged as a novel prognostic combination reflecting systemic inflammation, coagulopathy, and hepatic stress. This study identifies 6 clinically accessible biomarkers for mortality risk stratification in immunocompromised hosts with P aeruginosa LRTI, with the neutrophil-DLR-AST triad representing a new prognostic model. The developed model offers clinicians a practical tool for early high-risk patient identification and personalized management. While highlighting the interaction between inflammatory regulation, coagulation abnormalities, and organ dysfunction in determining outcomes, these findings require prospective validation in multicenter cohorts. Future research should elucidate the pathophysiological mechanisms linking these biomarkers to disease progression and explore targeted interventions based on individualized risk profiles.
- Top Cited PapersOpen Access
- 13 March 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-15
The global, regional, and national patterns of change in the burden of chronic kidney disease from 1990 to 2021
Chronic kidney disease (CKD) is a major global public health problem with increasing prevalence and a huge health and economic burden. Diabetes mellitus and hypertension are major risk factors for CKD, and CKD is associated with cardiovascular disease and end-stage renal disease. Understanding the prevalence and burden of CKD is essential for the development of prevention and control strategies. Using data from the Global Burden of Disease Study (GBD) 2021 study, this study analyzed the incidence, prevalence, and disability-adjusted life years (DALYs) of CKD at global, regional, and national levels between 1990 and 2021. Decomposition analysis, health inequalities and frontier analysis were used to analyse the changes. This study analyzed the global regional and national burden, trends, and disparities of CKD from 1990 to 2021 and found that the global burden of CKD had increased significantly, in line with trends in population ageing and population growth, and with significant variations between regions. There were 673.7 million people with CKD worldwide in 2021, accounting for 8.54% of the global population, a 92.0% increase from 1990. Despite a slight decline in age-standardized prevalence rate (ASPR), the absolute number of CKD cases increased. Central Asia had the highest prevalence of CKD, while Central Latin America had the highest rate of DALYs and incidence for CKD. In 2021, At the national level, China had the highest number of new CKD cases. The country with the highest ASPR and age-standardized DALYs rate (ASDR) of CKD was Mauritius. Globally, age-standardized incidence rate (ASIR) and ASDR were on the rise in almost all countries/regions, suggesting that the impact of CKD on global health is increasing. Population growth and ageing were major factors contributing to the increasing burden of CKD, especially in China and low Socio-demographic Index (SDI) regions. In addition, the cross-national study of health inequalities in CKD showed that, although there have been improvements in global health over time, health inequalities continue to exist. The frontier analysis revealed a considerable degree of heterogeneity in the effective differences across the spectrum of socio-demographic indices. CKD is a global health problem, the burden of which varies between regions and countries. A multifaceted approach is necessary to prevent and control CKD, including population-level interventions targeting risk factors, improvements in the accessibility and quality of health care, and measures to address health inequalities.
- 13 March 2025
- Published by Springer Nature in BMC Nephrology
- Vol. 26 (1) , 1-15
Top Cited PapersOpen AccessThe global, regional, and national patterns of change in the burden of chronic kidney disease from 1990 to 2021
Chronic kidney disease (CKD) is a major global public health problem with increasing prevalence and a huge health and economic burden. Diabetes mellitus and hypertension are major risk factors for CKD, and CKD is associated with cardiovascular disease and end-stage renal disease. Understanding the prevalence and burden of CKD is essential for the development of prevention and control strategies. Using data from the Global Burden of Disease Study (GBD) 2021 study, this study analyzed the incidence, prevalence, and disability-adjusted life years (DALYs) of CKD at global, regional, and national levels between 1990 and 2021. Decomposition analysis, health inequalities and frontier analysis were used to analyse the changes. This study analyzed the global regional and national burden, trends, and disparities of CKD from 1990 to 2021 and found that the global burden of CKD had increased significantly, in line with trends in population ageing and population growth, and with significant variations between regions. There were 673.7 million people with CKD worldwide in 2021, accounting for 8.54% of the global population, a 92.0% increase from 1990. Despite a slight decline in age-standardized prevalence rate (ASPR), the absolute number of CKD cases increased. Central Asia had the highest prevalence of CKD, while Central Latin America had the highest rate of DALYs and incidence for CKD. In 2021, At the national level, China had the highest number of new CKD cases. The country with the highest ASPR and age-standardized DALYs rate (ASDR) of CKD was Mauritius. Globally, age-standardized incidence rate (ASIR) and ASDR were on the rise in almost all countries/regions, suggesting that the impact of CKD on global health is increasing. Population growth and ageing were major factors contributing to the increasing burden of CKD, especially in China and low Socio-demographic Index (SDI) regions. In addition, the cross-national study of health inequalities in CKD showed that, although there have been improvements in global health over time, health inequalities continue to exist. The frontier analysis revealed a considerable degree of heterogeneity in the effective differences across the spectrum of socio-demographic indices. CKD is a global health problem, the burden of which varies between regions and countries. A multifaceted approach is necessary to prevent and control CKD, including population-level interventions targeting risk factors, improvements in the accessibility and quality of health care, and measures to address health inequalities.
- Open Access
- 6 July 2023
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 27 (17) , 2482-2494
Classification and characterisation of extracellular vesicles‐related tuberculosis subgroups and immune cell profiles
Around the world, tuberculosis (TB) remains one of the most common causes of morbidity and mortality. The molecular mechanism ofMycobacterium tuberculosis(Mtb) infection is still unclear. Extracellular vesicles (EVs) play a key role in the onset and progression of many disease states and can serve as effective biomarkers or therapeutic targets for the identification and treatment of TB patients. We analysed the expression profile to better clarify the EVs characteristics of TB and explored potential diagnostic markers to distinguish TB from healthy control (HC). Twenty EVs‐related differentially expressed genes (DEGs) were identified, and 17 EVs‐related DEGs were up‐regulated and three DEGs were down‐regulated in TB samples, which were related to immune cells. Using machine learning, a nine EVs‐related gene signature was identified and two EVs‐related subclusters were defined. The single‐cell RNA sequence (scRNA‐seq) analysis further confirmed that these hub genes might play important roles in TB pathogenesis. The nine EVs‐related hub genes had excellent diagnostic values and accurately estimated TB progression. TB's high‐risk group had significantly enriched immune‐related pathways, and there were substantial variations in immunity across different groups. Furthermore, five potential drugs were predicted for TB using CMap database. Based on the EVs‐related gene signature, the TB risk model was established through a comprehensive analysis of different EV patterns, which can accurately predict TB. These genes could be used as novel biomarkers to distinguish TB from HC. These findings lay the foundation for further research and design of new therapeutic interventions aimed at treating this deadly infectious disease.
- 6 July 2023
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 27 (17) , 2482-2494
Open AccessClassification and characterisation of extracellular vesicles‐related tuberculosis subgroups and immune cell profiles
Around the world, tuberculosis (TB) remains one of the most common causes of morbidity and mortality. The molecular mechanism ofMycobacterium tuberculosis(Mtb) infection is still unclear. Extracellular vesicles (EVs) play a key role in the onset and progression of many disease states and can serve as effective biomarkers or therapeutic targets for the identification and treatment of TB patients. We analysed the expression profile to better clarify the EVs characteristics of TB and explored potential diagnostic markers to distinguish TB from healthy control (HC). Twenty EVs‐related differentially expressed genes (DEGs) were identified, and 17 EVs‐related DEGs were up‐regulated and three DEGs were down‐regulated in TB samples, which were related to immune cells. Using machine learning, a nine EVs‐related gene signature was identified and two EVs‐related subclusters were defined. The single‐cell RNA sequence (scRNA‐seq) analysis further confirmed that these hub genes might play important roles in TB pathogenesis. The nine EVs‐related hub genes had excellent diagnostic values and accurately estimated TB progression. TB's high‐risk group had significantly enriched immune‐related pathways, and there were substantial variations in immunity across different groups. Furthermore, five potential drugs were predicted for TB using CMap database. Based on the EVs‐related gene signature, the TB risk model was established through a comprehensive analysis of different EV patterns, which can accurately predict TB. These genes could be used as novel biomarkers to distinguish TB from HC. These findings lay the foundation for further research and design of new therapeutic interventions aimed at treating this deadly infectious disease.
- 15 June 2022
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 100 (7) , 1057-1070
Statin therapy protects against abdominal aortic aneurysms by inducing the accumulation of regulatory T cells in ApoE−/− mice
CD4+CD25+ regulatory T cells (Tregs) have been shown to protect against abdominal aortic aneurysm (AAA) progression. Statins have immunomodulatory properties, and their effect on AAA partly depends on immune-related mechanisms. In this study, we aimed to explore whether there is an association between statins and Tregs in AAA progression. Sixty ApoE−/− mice were randomly divided into four groups (n = 15 per group): A, saline group; B, control group; C, simvastatin group (intragastric administration of simvastatin); and D, PC61 group (simvastatin combined with an intraperitoneal injection of 100 μg CD25-depleting antibody PC61). After 2 weeks of simvastatin treatment, the mice received a continuous subcutaneous infusion of angiotensin II (Ang II; B, C, and D groups) or saline (A group) for 28 days. Simvastatin therapy for 6 weeks significantly decreased the incidence and severity of AAA and inhibited the apoptosis of smooth muscle cells and generation of reactive oxygen species, which was partly abolished after the injection of PC61 antibody. Importantly, simvastatin increased the number of Tregs and the levels of Treg-associated cytokines (TGF-β and IL-10) and decreased the level of IL-17 both in aortic tissues and serum. Interestingly, simvastatin attenuated Ang II-induced gut microbial dysbiosis, which might be associated with the accumulation of Tregs. In conclusion, simvastatin therapy prevented the development of AAA induced by Ang II in ApoE−/− mice, which might be partly due to the induction of Treg accumulation. In addition, simvastatin regulated gut microbial dysbiosis, which might also be associated with Treg generation.
- 15 June 2022
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 100 (7) , 1057-1070
Statin therapy protects against abdominal aortic aneurysms by inducing the accumulation of regulatory T cells in ApoE−/− mice
CD4+CD25+ regulatory T cells (Tregs) have been shown to protect against abdominal aortic aneurysm (AAA) progression. Statins have immunomodulatory properties, and their effect on AAA partly depends on immune-related mechanisms. In this study, we aimed to explore whether there is an association between statins and Tregs in AAA progression. Sixty ApoE−/− mice were randomly divided into four groups (n = 15 per group): A, saline group; B, control group; C, simvastatin group (intragastric administration of simvastatin); and D, PC61 group (simvastatin combined with an intraperitoneal injection of 100 μg CD25-depleting antibody PC61). After 2 weeks of simvastatin treatment, the mice received a continuous subcutaneous infusion of angiotensin II (Ang II; B, C, and D groups) or saline (A group) for 28 days. Simvastatin therapy for 6 weeks significantly decreased the incidence and severity of AAA and inhibited the apoptosis of smooth muscle cells and generation of reactive oxygen species, which was partly abolished after the injection of PC61 antibody. Importantly, simvastatin increased the number of Tregs and the levels of Treg-associated cytokines (TGF-β and IL-10) and decreased the level of IL-17 both in aortic tissues and serum. Interestingly, simvastatin attenuated Ang II-induced gut microbial dysbiosis, which might be associated with the accumulation of Tregs. In conclusion, simvastatin therapy prevented the development of AAA induced by Ang II in ApoE−/− mice, which might be partly due to the induction of Treg accumulation. In addition, simvastatin regulated gut microbial dysbiosis, which might also be associated with Treg generation.
- Open Access
- 10 December 2013
- Published by Springer Nature in Cell Research
- Vol. 24 (2) , 218-232
A novel mechanism underlies caspase-dependent conversion of the dicer ribonuclease into a deoxyribonuclease during apoptosis
During C. elegans apoptosis, the dicer ribonuclease (DCR-1) is cleaved by the cell death protease CED-3 to generate a truncated DCR-1 (tDCR-1) with one and a half ribonuclease III (RNase III) domains, converting it into a deoxyribonuclease (DNase) that initiates apoptotic chromosome fragmentation. We performed biochemical and functional analyses to understand this unexpected RNase to DNase conversion. In full-length DCR-1, tDCR-1 DNase activity is suppressed by its N-terminal DCR-1 sequence. However, not all the sequence elements in the N-terminal DCR-1 are required for this suppression. Our deletion analysis reveals that a 20-residue α-helix sequence in DCR-1 appears to define a critical break point for the sequence required for suppressing tDCR-1 DNase activity through a structure-dependent mechanism. Removal of the N-terminal DCR-1 sequence from tDCR-1 activates a DNA-binding activity that also requires the one half RNase IIIa domain, and enables tDCR-1 to process DNA. Consistently, structural modeling of DCR-1 and tDCR-1 suggests that cleavage of DCR-1 by CED-3 may cause a conformational change that allows tDCR-1 to bind and process DNA, and may remove steric hindrance that blocks DNA access to tDCR-1. Moreover, a new DNase can be engineered using different RNase III domains, including the one from bacterial RNase III. Our results indicate that very distantly related RNase III enzymes have the potential to cleave DNA when processed proteolytically or paired with an appropriate partner that facilitates binding to DNA. We suggest the possibility that this phenomenon may be extrapolated to other ribonucleases.
- 10 December 2013
- Published by Springer Nature in Cell Research
- Vol. 24 (2) , 218-232
Open AccessA novel mechanism underlies caspase-dependent conversion of the dicer ribonuclease into a deoxyribonuclease during apoptosis
During C. elegans apoptosis, the dicer ribonuclease (DCR-1) is cleaved by the cell death protease CED-3 to generate a truncated DCR-1 (tDCR-1) with one and a half ribonuclease III (RNase III) domains, converting it into a deoxyribonuclease (DNase) that initiates apoptotic chromosome fragmentation. We performed biochemical and functional analyses to understand this unexpected RNase to DNase conversion. In full-length DCR-1, tDCR-1 DNase activity is suppressed by its N-terminal DCR-1 sequence. However, not all the sequence elements in the N-terminal DCR-1 are required for this suppression. Our deletion analysis reveals that a 20-residue α-helix sequence in DCR-1 appears to define a critical break point for the sequence required for suppressing tDCR-1 DNase activity through a structure-dependent mechanism. Removal of the N-terminal DCR-1 sequence from tDCR-1 activates a DNA-binding activity that also requires the one half RNase IIIa domain, and enables tDCR-1 to process DNA. Consistently, structural modeling of DCR-1 and tDCR-1 suggests that cleavage of DCR-1 by CED-3 may cause a conformational change that allows tDCR-1 to bind and process DNA, and may remove steric hindrance that blocks DNA access to tDCR-1. Moreover, a new DNase can be engineered using different RNase III domains, including the one from bacterial RNase III. Our results indicate that very distantly related RNase III enzymes have the potential to cleave DNA when processed proteolytically or paired with an appropriate partner that facilitates binding to DNA. We suggest the possibility that this phenomenon may be extrapolated to other ribonucleases.